Skip to content
Facebook Twitter Linkedin
InMed-logo-01
  • Pharmaceutical
    • INM-901 for Alzheimer’s Disease
    • INM-089 for Age-related Macular Degeneration
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Novel Analogs
  • Manufacturing
    • BayMedica – Rare Cannabinoid Ingredients
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
    • Investor Contact
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisors
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn
  • Pharmaceutical
    • INM-901 for Alzheimer’s Disease
    • INM-089 for Age-related Macular Degeneration
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Novel Analogs
  • Manufacturing
    • BayMedica – Rare Cannabinoid Ingredients
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
    • Investor Contact
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisors
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn

Filings

Form TypeForm DescriptionFiling DateReport DateView Report
CORRESPCorrespondence4/14/2022
UPLOADSEC-generated letter4/14/2022
4Statement of changes in beneficial ownership of securities4/13/20224/13/2022
3Initial statement of beneficial ownership of securities4/8/20224/1/2022
S-3Registration statement under Securities Act of 19334/7/2022
424B3Prospectus [Rule 424(b)(3)]4/7/2022
8-KCurrent report4/7/20224/7/2022
8-KCurrent report3/22/20223/21/2022
8-KCurrent report3/18/20223/17/2022
8-KCurrent report3/9/20223/8/2022
4Statement of changes in beneficial ownership of securities2/28/20222/23/2022
4Statement of changes in beneficial ownership of securities2/23/20222/20/2022
8-KCurrent report2/23/20222/11/2022
3Initial statement of beneficial ownership of securities2/22/20222/11/2022
4Statement of changes in beneficial ownership of securities2/22/20222/18/2022
8-KCurrent report2/15/20222/14/2022
8-KCurrent report2/15/20222/15/2022
10-QQuarterly report [Sections 13 or 15(d)]2/14/202212/31/2021
EFFECTNotice of Effectiveness2/11/2022
EFFECTNotice of Effectiveness2/11/2022
CORRESPCorrespondence2/10/2022
8-KCurrent report2/10/20222/10/2022
S-3/ARegistration statement under Securities Act of 1933 - amendment2/9/2022
CORRESPCorrespondence2/9/2022
UPLOADSEC-generated letter2/8/2022
UPLOADSEC-generated letter2/8/2022
SC 13G/AStatement of acquisition of beneficial ownership by individuals - amendment2/4/2022
S-3Registration statement under Securities Act of 19332/4/2022
S-3Registration statement under Securities Act of 19332/4/2022
4Statement of changes in beneficial ownership of securities1/24/20221/24/2022
  • « Previous
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • …
  • 14
  • Next »

Investor Alerts

Sign up for investor alerts!
Sign Up

Information Request

Send us a request for information
Learn More
InMed-logo-mono

#1455 – 885 West Georgia St.
Vancouver, BC, Canada
V6C 3E8

Pharmaceutical

  • INM-901 for Alzheimer’s Disease
  • INM-089 for Age-related Macular Degeneration
  • INM-755 for Epidermolysis Bullosa
  • INM-088 for Glaucoma
  • Novel Analogs

MANUFACTURING

  • BayMedica – Rare Cannabinoid Ingredients
  • Cannabinoid Manufacturing Expertise
  • IntegraSyn™ Cannabinoid Manufacturing

Investor

  • News
  • Events
  • Stock Information
  • Corporate Governance
  • Financials & AGM Materials
  • Filings
  • Presentations
  • Media & Videos
  • Investor Contact

CORPORATE

  • Management
  • Board of Directors
  • Scientific Advisors
  • Partners and Collaborators
  • Careers
  • Contact

Learn

  • What is Cannabinol (CBN)?
  • What is Epidermolysis Bullosa (EB)?
  • What is Glaucoma?
  • Cannabinoid Manufacturing Economics 101
  • GMP Manufacturing Standards by Product Type
  • Cannabinoids for Glaucoma
  • Cannabinoid Science
  • Articles and Videos

© Copyright 2025 InMed Pharmaceuticals Inc.

  • Privacy Policy
  • Terms of Use
  • Legal Disclaimer
  • Find Us On:
Subscribe

Sign up to receive emails from InMed Pharmaceuticals

"*" indicates required fields

Name*
Consent*